Takeda’s cancer prospects dim further
After trimming its cell therapy pipeline last year, the group is now out entirely.
Orca heads to the FDA
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
Atara still can't get across the US finish line
Just when investors thought things couldn't get any worse, they do.
Gilead and Galapagos's conscious uncoupling
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
Protara could take on J&J
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
The pieces of Vor’s puzzle start to come together
The depressed company could use Mylotarg as a stepping stone in AML.
EHA 2024 – In8bio bets on a registrational plan
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
